Merck Stock Dips as Keytruda Concerns Weigh on Investors

Merck & Co Inc (MRK) saw its stock price drop by 3.04% on October 5, as investors reassessed the company's long-term growth prospects against its current valuation. The decline came after a period of strong performance, with market attention now focused on Keytruda, Merck's flagship oncology treatment, which accounts for roughly half of the company's total sales. Concerns about moderating domestic growth rates and the eventual loss of Keytruda's patent exclusivity later in the decade have contributed to a more cautious outlook among institutional investors.

The downward trend was exacerbated by technical factors and institutional portfolio adjustments. The stock fell below its short-term moving average, triggering technical selling as momentum traders reacted to key support levels. Recent regulatory disclosures also revealed that several institutional asset managers had reduced their positions, along with prior insider share sales, which further dampened market sentiment.

Investors are also preparing for Merck's upcoming third-quarter earnings release, which has led to defensive de-risking. Despite Merck's progress in advancing its late-stage pipeline across oncology, cardiometabolic, and vaccine candidates, market participants remain selective. The company will need to provide updated operational guidance and clearer commercialization timelines to address future revenue challenges and alleviate current market concerns.

Technical indicators for Merck & Co Inc (MRK) include a MACD (12,26,9) value of -2.373, signaling a neutral outlook. The RSI stands at 38.498, indicating a neutral condition, while the Williams %R at 98.993 suggests an oversold condition. Analysts have rated the company as a Buy, with an average price target of $151.95, though some have issued downgrades due to concerns over Keytruda's exclusivity and potential revenue cliffs.